Key references: Intracavernosal therapy for erectile dysfunction

Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol 2018;200(3):633–41. https://www.ncbi.nlm.nih.gov/pubmed/29746858
Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men-2017. J Sex Med 2018;15(4):430–57. https://www.ncbi.nlm.nih.gov/pubmed/29550461
Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334(14):873–7. https://www.ncbi.nlm.nih.gov/pubmed/8596569
Olujohungbe A, Burnett AL. How I manage priapism due to sickle cell disease. Br J Haematol 2013;160(6):754–65. https://www.ncbi.nlm.nih.gov/pubmed/23293942
Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Priapism. J Sex Med 2004;1(1):116–20. https://www.ncbi.nlm.nih.gov/pubmed/16422992
Rodgers R, Latif Z, Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol 2012;158(2):155–64. https://www.ncbi.nlm.nih.gov/pubmed/22571386
Sadeghi-Nejad H, Seftel AD. The etiology, diagnosis, and treatment of priapism: review of the American Foundation for Urologic Disease Consensus Panel Report. Curr Urol Rep 2002;3(6):492–8. https://www.ncbi.nlm.nih.gov/pubmed/12425873